ARTICLE | Finance
Modulating sepsis
Rationale for investing EUR 18 million in preclinical sepsis play Inotrem
March 24, 2014 7:00 AM UTC
Sepsis is among the most intractable indications in drug development, but Inotrem S.A. and its series A investors think the company's peptide inhibitors of TREM1 may succeed where all others have failed.
New investors Edmond de Rothschild Investment Partners (EdRIP) and Sofinnova Partners co-led the €18 million ($25 million) round. New investors Biomed Invest and the French National Institute of Health and Medical Research (Inserm) Transfert Initiative also participated...